S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.17%) $0.928
USD/NOK
(0.34%) $10.88
USD/GBP
(-0.03%) $0.792
USD/RUB
(-0.35%) $92.26

Realtime updates for CureVac N.V. [5CV.F]

Exchange: XETRA Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 12:21

2.15% 2.85

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 12:21):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA)...

Stats
Today's Volume 9 063.00
Average Volume 14 820.00
Market Cap 638.07M
EPS €-0.217 ( 2023-09-30 )
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E -1.940
ATR14 €0.0140 (0.49%)

CureVac N.V. Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CureVac N.V. Financials

Annual 2022
Revenue: €67.42M
Gross Profit: €-116.57M (-172.91 %)
EPS: €-1.320
Q3 2023
Revenue: €16.48M
Gross Profit: €-7.80M (-47.31 %)
EPS: €-0.220
Q2 2023
Revenue: €7.58M
Gross Profit: €-18.28M (-241.13 %)
EPS: €-0.300
Q1 2023
Revenue: €7.13M
Gross Profit: €-13.51M (-189.45 %)
EPS: €-0.270

Financial Reports:

No articles found.

CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators